Abstract: Background Magnetic resonance imaging (MRI) of pacemaker patients is contraindicated due to documented potential risks to the patient from hazardous interactions between the MRI and pacemaker system. Objective The purpose of this prospective, randomized, controlled, worldwide clinical trial was to evaluate the safety and effectiveness of a pacemaker system designed for safe use in MRI for any bradycardia indicated patient. Methods Patients (n = 464) were randomized to undergo an MRI scan between 9 and 12 weeks postimplant (MRI group, n = 258) or not to undergo MRI (control group, n = 206) after successful implantation of the specially designed dual-chamber pacemaker and leads. Patients were monitored for arrhythmias, symptoms, and pacemaker system function during 14 nonclinically indicated relevant brain and lumbar MRI sequences. Sequences were performed at 1.5 T and included scans with high radiofrequency power deposition and/or high gradient dB/dt exposure. Clinical evaluation of the pacemaker system function occurred immediately before and after MRI, 1 week and 1 month post-MRI, and at corresponding times for the control group. Primary endpoints for safety analyzed the MRI procedure complication-free rate and for effectiveness compared capture and sensing performance between MRI and control groups. Results No MRI-related complications occurred during or after MRI, including sustained ventricular arrhythmias, pacemaker inhibition or output failures, electrical resets, or other pacemaker malfunctions. Pacing capture threshold and sensed electrogram amplitude changes were minimal and similar between study groups. Conclusion This trial documented the ability of this pacemaker system to be exposed in a controlled fashion to MRI in a 1.5 T scanner without adverse impact on patient outcomes or pacemaker system function. Medtronic, Inc. provided funding for this trial, and is the manufacturer of the dualchamber pacemaker system used in the trial.
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Abstract and Keywords
Background: Magnetic Resonance Imaging (MRI) of pacemaker patients is contraindicated due to documented potential risks to the patient from hazardous interactions between the MRI and pacemaker system.
Objective: This prospective, randomized controlled, worldwide clinical trial evaluated safety and effectiveness of a pacemaker system designed for safe use in MRI for any bradycardia indicated patient.
Method: Patients (n=464) were randomized to undergo an MRI scan between 9-12 weeks post-implant (MRI group, n=258) or not to undergo MRI (control group, n=206) after successful implantation of the specially designed dual chamber pacemaker and leads. Patients were monitored for arrhythmias, symptoms and pacemaker system function during 14 non clinically indicated relevant brain and lumbar MRI sequences.
Sequences were performed at 1.5 Tesla (T) and included scans with high radiofrequency power deposition and/or high gradient dB/dt exposure. Clinical evaluation of the pacemaker system function occurred immediately before and after MRI, 1-week and 1-month post-MRI and at corresponding times for the control group. Primary endpoints for safety analyzed the MRI procedure complication-free rate, and for effectiveness compared capture and sensing performance between MRI and control groups. 
Conclusion:
This trial documented the pacemaker system's ability to be exposed in a controlled fashion to MRI in a 1.5T scanner without adverse impact on patient outcomes or pacemaker system function. 
Keywords
Introduction
Safe Access to MRI is a Critical Need for Pacemaker Patients
The use of Magnetic Resonance Imaging (MRI) as the imaging modality of choice in many fields (e.g. brain, spinal cord and musculoskeletal system) is rapidly increasing.
However, manufacturers of cardiac devices and of MRI systems contraindicate MRI for patients with implanted pacemaker systems due to multiple associated risks.
Approximately 5,000,000 patients worldwide are currently implanted with a pacemaker or implantable cardioverter defibrillator (ICD) and at least 50% of these patients are expected to be indicated to undergo clinical MRI over the lifetime of their device. 
Risks associated with MRI scans of pacemaker patients
Literature documents that there are several interactions between the MRI associated static magnetic field, gradient fields and radiofrequency (RF) field and the implanted pacemaker system may be hazardous to the patient and/or damage the device. [2] [3] [4] Despite the potential for adverse outcomes, a few centers perform MRI scanning of carefully selected pacemaker patients using precautions when the benefit outweighs the risk. Even in these centers and under extensive expert supervision, clinically significant irregular pacemaker system behavior cannot always be prevented or good patient outcomes assured. to mitigate these hazards provides access to pacemaker patients for this important diagnostic modality. The aim of the trial was to evaluate safety and efficacy of this novel pacemaker system during MRI in a prospective, randomized, multicenter trial.
Methods
Pacemaker system
The following design modifications were made to the pacemaker system to improve MRI compatibility: 1) The leads were modified to reduce RF lead tip heating, 2) Internal circuits were changed to reduce the potential for cardiac stimulation, 3) The amount of ferromagnetic materials was limited, 4) Internal circuit protection was improved to prevent disruption of the internal power supply, 5) The reed switch was replaced by a
Hall sensor, whose behavior in a static magnetic field is predictable and 6) A dedicated programming care pathway was developed to facilitate the choice between asynchronous versus non-stimulation modes, increase the pacing output to 5.0V / 1.0 ms during MRI scanning, prevent programming the MRI mode if the device fails any of the 10 system integrity checks and facilitate restoration of pre-scan program states and values. (Table 1) Conditions for safely scanning patients with this system during this trial required a static magnetic field strength of 1.5T, a maximum Specific Absorption Rate (SAR) value of 2W/kg for each sequence and a maximum gradient slew rate of 200T/m/s.
Furthermore, the position of the isocenter of the RF transmitter coil must be above the superior surface of the C1 vertebra or below the inferior surface of the body of T12. 
Data collection and analysis
After a successful pacemaker and lead implantation, randomization was performed to either undergo an MRI scan (MRI group) or not to undergo an MRI scan (Control) at 9-12 weeks after system implantation. Initially patients were randomized 1:1 but later changed to 2:1 to meet the regulatory requirement for >200 scanned patients. 
MRI
The MRI scans were performed with 1.5T systems from three MRI manufacturers interference, electrocardiographic monitoring provided inaccurate assessments of heart rate and rhythm. Instead, pulse oximetry provided the ability to continuously monitor heart rate and oxygen saturation and was not affected by the MRI fields. Patients were also monitored using verbal communication and when available, non-invasive blood pressure monitoring.
Statistics
To assess if the MRI related complication-free rate in the month following the MRI was greater than 90%, a one-sided one-sample exact test of binomial proportions along with a one-sided 97.5% confidence interval (CI) were calculated.
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The proportion of patients who experienced a change in PCT of ≤0.5V at 0.5ms from before the MRI/control visit to the1-month post visit were tested for equivalence between MRI and control groups by using a two-sample 97.5% confidence interval, with
Farrington-Manning p-values. The equivalence margin was 10%. The proportion of patients who experienced a change in sensing amplitudes from before the MRI/control visit to the 1-month post visit were tested for statistical equivalence between the MRI and control group by two-sample one-sided 97.5% CI, with p-values from the FarringtonManning test for equivalence of proportions. Success was achieved if the sensing amplitude decreased less than or equal to 50% and the amplitude remained above a clinically acceptable minimum of 1.5mV in the atrium or 5.0mV in the ventricle.
Pre-specified analysis exclusion criteria were listed in the protocol. Additional analyses were performed to include excluded data from the PCT and sensing analyses.
The proportion of patients free of system-related complications related from implant until 1-month post-MRI/control visit was compared to a value of 80% by a one-sided onesample exact test with one-sided 95% CI.
Statistics were performed by Medtronic and re-evaluated by the Cleveland Clinic
Coordinating Center for Clinical Research (C5 Research), Cleveland, OH, US.
Adverse Event Classification
All adverse events were classified in several ways by an adverse events committee:
according to their relationship to the implant procedure, to the MR procedure, and to the pacing system. In some cases, adverse events were classified as having an unclear relationship to the implant, MR or pacing system due to the inability to assign the 9 29 Sep 2010 component of the system or procedure. In addition, adverse events were classified as either complications or observations. The definition of a complication was predefined as an adverse event that resulted in an invasive intervention or the termination of significant device function. The definition of an observation was predefined as an adverse event that
was not a complication.
Independent data monitoring, MRI scan advisory, and adverse events committees reviewed information and provided recommendations.
Results
Trial population
A total of 464 patients were randomized after successful pacemaker system implantation While there were no MRI complications, there were eight observations which were either classified as being MRI related or unclear if related to the MRI procedure. Four patients reported paraesthesia (n=3) and palpitation symptoms (n=1), which were identified as related to the MRI, required no invasive actions and all resolved the same day as the MRI. These events are typical events seen among patients who receive MRIs.
Another four patients reported mild transient chest pressure (n=1), swallowing problems (n=1), atrial flutter (n=1) and atrial fibrillation symptoms (n=1), which were assessed as having an unknown relationship to the MRI, but no relationship to the pacemaker system and required no invasive interventions.
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Over the course of the trial eleven deaths occurred, including nine in the MRI group.
None were related to the MRI procedure, implantation procedure or pacemaker system. and control deaths appears to be a statistical variant, with no clear relationship of mode of death.
The proportion of patients free of pacemaker system-related complications through the 1-month post-MRI/control visit was expected to be greater than 80% and was measured to be 91.7% (410/447), with a one-sided 95% CI of 89.3% (p<0.001). A total of 37 patients experienced 43 system-related complications exhibited as lead dislodgement (n=17), elevated capture thresholds (n=9), pericardial effusion (n=3) and failure to capture (n=3). None of these were related to MRI.
Pacing capture threshold equivalence
The immediately after the MRI and to 2.5V at 1-month post-MRI visit. In this patient PCT returned to 2V at the 12-month visit. Also in this patient the SAR limit of 2 W/kg was exceeded for one lumbar scan sequence (2.5W/kg) when performing the full set of brain and lumbar scans, the only such instance in the eight patients in whom the SAR limit was exceeded. The upper bound of the one-sided 97.5% confidence limit was 1.4%. This additional analysis supported that the PCT success rates of the two groups were equivalent.
Sensing equivalence
There was clinical equivalence of the proportion of patients who maintained the sensed the MRI/control visit to the 1-month post visit were clinically equivalent between MRI and control groups. All pacemaker system-related complications were within an expected and clinically acceptable range. [8] [9] [10] These results indicate that this pacemaker system can be used safely in an MRI environment when used in accordance with its labeling.
RF-induced heating
Heating of pacemaker leads during MRI has been shown to depend on numerous parameters including the amount of transmitted RF energy (quantified by the SAR), patient size and anatomy, patient position within the scanner bore, and the position of the pacemaker lead within the RF field. [11] [12] [13] [14] Furthermore, heating depends on the specific lead design and lead length. Variations among different lead models can result in different risks of lead tip heating. 15 Publications have shown that substantial increases in PCT 16, 17 and serum troponin 16 can be observed after MRI at 1.5T in patients implanted with conventional pacemakers.
PCT changes have been attributed to RF-induced heating of the cardiac tissue in proximity to the pacemaker lead tip, resulting in thermal injury. 16 , These findings of potential RF-related thermal injury are further supported by in-vitro experiments 4, 18, 19 and in-vivo animal studies. 3, 4 The leads of this new pacemaker system were modified to reduce lead tip heating 
Unintended Cardiac Stimulation
Gradient magnetic and RF electromagnetic fields produced by MRI scanners induce pulsed voltages in pacemaker leads that are conducted to the heart at the myocardialelectrode interface. If these MRI-induced voltage pulses are large enough, they could directly stimulate the heart, which is known as unintended cardiac stimulation (UCS).
Clinical manifestations of UCS due to single or multiple captured beats include palpitations or hemodynamic collapse and potentially fatal sustained ventricular tachycardia. Out of 227 patients exposed to the MRI scanning protocol who were monitored via pulse oximetry, there were no UCS adverse events reported with relationship to the MRI procedure.
Interference with pacemaker function
In the strong static magnetic field of the MRI unit, the reed switch state (open or closed) and the pacemaker (synchronous or asynchronous) is not always predictable. 20 If the pacemaker stays in synchronous mode during an MRI examination, the gradient field can mimic intrinsic cardiac electrical activity, and, thus, inhibit pacemaker output 21 , which may be fatal for a pacemaker-dependent patient. On the other hand, fixed cardiac pacing in an asynchronous mode due to MRI-related closure of the reed switch may lead to competitive rhythms (intrinsic rhythm and fixed pacemaker stimulation), creating a risk of inducing possibly fatal tachyarrhythmias.
22, 23
The use of a Hall sensor mitigates this risk, whose behavior in the MRI environment is predictable, and by including a specific MRI operation feature. With this feature, the Hall sensor is suspended and is not influenced by the static magnetic field; the physician can 17 29 Sep 2010 choose either to program the pacemaker to an asynchronous pacing mode or to a nonpacing mode. Asynchronous pacing will maintain appropriate pacing support throughout the MRI examination regardless of the noise sensed by the pacemaker system and without the risk of pacing output inhibition. For patients who are non-pacemaker dependent, the non-pacing mode is available.
Electrical Reset
An electrical reset is an emergency safety feature that guarantees minimal pacemaker functionality in case of battery voltage dips due to electromagnetic interference or battery
depletion. An electrical reset will cause a change in the programmed parameters to basic settings, and to an inhibited pacing mode (VVI) with a manufacturer determined stimulation rate.
Previously, electrical reset has been reported on exposure to the MRI field in six percent of pacemaker patients undergoing MRI. 16 An electrical reset has important safety 
Comparison with conventional pacemakers used off-label
It is notable that in previous studies 5, 16 that performed MRI scans on patients with conventional pacemakers in off-label use, cardiac myocardial injury, as indicated by increases in PCT and troponin I levels, was not entirely eliminated, even with strict precautionary measures to minimize the risk of RF lead heating. This trial showed only one increase in PCT from pre-to post-MRI/control visit (control group) >0. 5V out of 425 leads (0.2%) compared with 6 PCT increases out of 195 leads (3.1%) 16 and 10 PCT increases out of 107 leads (9.4%) 5 in recent major studies. Furthermore, there were no observations of any MRI-induced electrical reset compared with 6% in a previous study 16 using conventional pacemakers. Therefore, these specific pulse generator, software and lead design changes decrease RF-induced heating and risk of electrical resets due to electromagnetic interference, and increase safety for pacemaker patients during MRI scanning.
Limitations
Use of MRI scanners on pacemaker patients was specifically limited to well-defined conditions in the trial and safe use outside of these conditions has not been demonstrated. invasive blood pressure monitoring were adequate to assess both the pulse rate and the overall well being of the patient.
Conclusion
MRI scanning of patients with this specific pacemaker system which was evaluated in the trial was performed safely with no adverse impact on either the patient or the pacemaker system. It is important to note that this safety is conditional upon the use of only this complete pacemaker system. Safety is also conditional upon the pacing system being evaluated to assure normal function and appropriate programming, as well as upon following specific limitations on the MR scan, including use in a 1.5T MRI scanner and specific scan protocols. This system designed for use in the MRI environment is expected to safely facilitate access by pacemaker patients to an increasingly important imaging modality. 
